… in a subgroup of patients with severe COVID-19,[13] leading to the hypothesis that anticytokine
therapy and, therefore, immunosuppression could alter symptoms and disease course in …

… In summary, the existing data do not show an increased risk of severe COVID-19 in patients
taking biologic therapies or targeted disease-modifying antirheumatic drugs. The effect of …

… immunocompromised paediatric patients were at no increased risk of severe COVID-19
during the first two waves of the COVID… admission due to acute severe COVID-19 or paediatric …

… ’ immune responses to vaccination and infection are frequently impaired leaving them more
vulnerable to prolonged high viral loads and severe complications of COVID-19. Those in …

… of patient groups remaining vulnerable to severe COVID-19 … Data on COVID-19 outcomes,
obtained during previous … patients, showed an association between severity of COVID-19 and …

… approved for the treatment of COVID-19 during the last … immunocompromised patients. Most
treatment guidelines are structured to whether the disease state is mild, moderate, or severe, …

… coronavirus disease 2019 (COVID-19) in a patient … severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) for at least 119 days. The patient had 3 admissions related to COVID-…

… for dexamethasone use in immunocompromised persons with severe COVID-19 seems …
general did not enroll many immunocompromised patients. Other anecdotal evidence exists …

… enable uncontrolled viral replication and clinical progression to severe disease. Given
this pathophysiology, immunocompromised patients may be at higher risk for severe COVID-19. …

… efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods…
cohort including immunocompromised hospitalized patients with severe COVID-19 treated …